FLEMINGTON, N.J.--(BUSINESS WIRE)--NovaDel Pharma Inc. (AMEX: NVD), a specialty pharmaceutical company developing oral spray formulations of a broad range of marketed treatments for serious diseases, today announced that its licensee, Hana Biosciences, has notified the Company that ongoing scale-up and stability experiments indicate that there is a need to make adjustments to the formulation and/or manufacturing process, and that there is likely to be a delay in the commercial launch of ZensanaTM. ZensanaTM is an oral spray formulation of ondansetron that is indicated for the prevention of chemotherapy- and radiation-induced and post-operative nausea and vomiting. Hana licensed from NovaDel exclusive North American rights to market ondansetron delivered through NovaDel’s proprietary oral spray delivery technology, and in connection with that agreement assumed full responsibility for all clinical, regulatory and manufacturing activities for ZensanaTM.
